iradimed corp - IRMD

IRMD

Close Chg Chg %
75.49 2.09 2.77%

Closed Market

77.58

+2.09 (2.77%)

Volume: 83.27K

Last Updated:

Oct 22, 2025, 4:00 PM EDT

Company Overview: iradimed corp - IRMD

IRMD Key Data

Open

$75.49

Day Range

75.49 - 78.06

52 Week Range

47.21 - 78.38

Market Cap

$960.23M

Shares Outstanding

12.72M

Public Float

8.05M

Beta

1.03

Rev. Per Employee

N/A

P/E Ratio

46.82

EPS

$1.63

Yield

87.43%

Dividend

$0.17

EX-DIVIDEND DATE

Aug 18, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

53.27K

 

IRMD Performance

1 Week
 
1.72%
 
1 Month
 
5.91%
 
3 Months
 
32.62%
 
1 Year
 
48.22%
 
5 Years
 
230.19%
 

IRMD Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About iradimed corp - IRMD

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Orlando, FL.

IRMD At a Glance

IRadimed Corp.
12705 Ingenuity Drive
Orlando, Florida 32826
Phone 1-407-677-8022 Revenue 73.24M
Industry Medical Specialties Net Income 19.23M
Sector Health Technology 2024 Sales Growth 11.714%
Fiscal Year-end 12 / 2025 Employees 160
View SEC Filings

IRMD Valuation

P/E Current 46.824
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 36.555
Price to Sales Ratio 9.60
Price to Book Ratio 8.052
Price to Cash Flow Ratio 27.44
Enterprise Value to EBITDA 28.575
Enterprise Value to Sales 8.889
Total Debt to Enterprise Value 0.00

IRMD Efficiency

Revenue/Employee 457,763.256
Income Per Employee 120,212.662
Receivables Turnover 6.938
Total Asset Turnover 0.769

IRMD Liquidity

Current Ratio 8.839
Quick Ratio 7.617
Cash Ratio 6.136

IRMD Profitability

Gross Margin 76.936
Operating Margin 29.989
Pretax Margin 33.144
Net Margin 26.261
Return on Assets 20.195
Return on Equity 24.31
Return on Total Capital 22.115
Return on Invested Capital 24.064

IRMD Capital Structure

Total Debt to Total Equity 0.178
Total Debt to Total Capital 0.178
Total Debt to Total Assets 0.157
Long-Term Debt to Equity 0.002
Long-Term Debt to Total Capital 0.002
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Iradimed Corp - IRMD

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
41.81M 53.30M 65.56M 73.24M
Sales Growth
+31.83% +27.48% +23.00% +11.71%
Cost of Goods Sold (COGS) incl D&A
9.76M 12.02M 15.40M 16.89M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
634.01K 670.67K 765.18K 817.66K
Depreciation
532.27K 569.55K 648.13K 585.54K
Amortization of Intangibles
101.73K 101.12K 117.05K 232.11K
COGS Growth
+19.92% +23.10% +28.15% +9.66%
Gross Income
32.05M 41.28M 50.16M 56.35M
Gross Income Growth
+35.95% +28.81% +21.50% +12.34%
Gross Profit Margin
+76.65% +77.45% +76.50% +76.94%
2021 2022 2023 2024 5-year trend
SG&A Expense
22.23M 25.65M 30.12M 34.39M
Research & Development
1.91M 2.28M 2.86M 2.83M
Other SG&A
20.33M 23.38M 27.26M 31.55M
SGA Growth
-8.62% +15.39% +17.42% +14.15%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
9.82M 15.63M 20.04M 21.96M
Non Operating Income/Expense
18.61K 553.10K 1.70M 2.31M
Non-Operating Interest Income
34.81K 581.85K 1.86M 2.19M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
9.84M 16.18M 21.74M 24.28M
Pretax Income Growth
+1,694.53% +64.50% +34.35% +11.67%
Pretax Margin
+23.52% +30.36% +33.16% +33.14%
Income Tax
510.82K 3.35M 4.55M 5.04M
Income Tax - Current - Domestic
14.63K 3.29M 5.96M 5.73M
Income Tax - Current - Foreign
1.44K 1.79K 2.83K 5.09K
Income Tax - Deferred - Domestic
494.75K 64.41K (1.42M) (697.65K)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
9.33M 12.83M 17.19M 19.23M
Minority Interest Expense
- - - -
-
Net Income
9.33M 12.83M 17.19M 19.23M
Net Income Growth
+581.19% +37.56% +34.02% +11.87%
Net Margin Growth
+22.30% +24.07% +26.22% +26.26%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
9.33M 12.83M 17.19M 19.23M
Preferred Dividends
- - - -
-
Net Income Available to Common
9.33M 12.83M 17.19M 19.23M
EPS (Basic)
0.7553 1.0211 1.3642 1.518
EPS (Basic) Growth
+569.00% +35.19% +33.60% +11.27%
Basic Shares Outstanding
12.35M 12.56M 12.60M 12.67M
EPS (Diluted)
0.7406 1.0152 1.3514 1.5046
EPS (Diluted) Growth
+573.27% +37.08% +33.12% +11.34%
Diluted Shares Outstanding
12.59M 12.64M 12.72M 12.78M
EBITDA
10.45M 16.30M 20.80M 22.78M
EBITDA Growth
+6,954.02% +55.94% +27.62% +9.53%
EBITDA Margin
+25.00% +30.58% +31.73% +31.11%

Snapshot

Average Recommendation BUY Average Target Price 75.00
Number of Ratings 1 Current Quarters Estimate 0.47
FY Report Date 12 / 2025 Current Year's Estimate 1.84
Last Quarter’s Earnings 0.46 Median PE on CY Estimate N/A
Year Ago Earnings 1.66 Next Fiscal Year Estimate 2.11
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 N/A 1 1
Mean Estimate 0.47 N/A 1.84 2.11
High Estimates 0.47 N/A 1.84 2.11
Low Estimate 0.47 N/A 1.84 2.11
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 2
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Iradimed Corp - IRMD

Date Name Shares Transaction Value
Apr 8, 2025 John F. Glenn CHIEF FINANCIAL OFFICER 11,592 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 7, 2025 James B. Hawkins Director 33,545 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 7, 2025 John F. Glenn CHIEF FINANCIAL OFFICER 8,767 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $42.53 per share 372,860.51
Apr 7, 2025 John F. Glenn CHIEF FINANCIAL OFFICER 11,592 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Iradimed Corp in the News